# Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia

> **NCT02491398** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 494 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Bendamustine + Rituximab

## Key facts

- **NCT ID:** NCT02491398
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2020-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02491398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02491398, "Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02491398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*